Bioavailability effect of methylprednisolone by polymeric micelles

Pharmaceutical Research

Volumn 25, Issue 1, 2008, Pages 39-47

  Chen, Ching Lin ^a   Chang, Shwu Fen ^b   Lee, Daniel ^c   Yang, Lang Yo ^b   Lee, Yi Hsuan ^b   Hsu, Chung Y ^b   Lin, Shwu Jiuan ^c   Liaw, Jiahorng ^c  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bcl xL; Bioavailability; Methylprednisolone; PM; Spinal cord

Indexed keywords

COPOLYMER; MESSENGER RNA; METHYLPREDNISOLONE; POLY(ETHYLENE OXIDE) POLY(PROPYLENE OXIDE) POLY(ETHYLENE OXIDE); PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; FLUORESCENCE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIGHT SCATTERING; MALE; MICELLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SPINAL CORD; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BCL-X PROTEIN; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMISTRY; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIGHT; MALE; METHYLPREDNISOLONE; MICELLES; MICROSCOPY, ATOMIC FORCE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; PROPYLENE GLYCOLS; RABBITS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCATTERING, RADIATION; SPINAL CORD INJURIES;

EID: 38049139283     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9484-0     Document Type: Article

References (51)

1. M. B. Bracken, M. J. Shepard, T. R. Holford, L., Leo-Summers, E. F. Aldrich, M. Fazl, M. Fehlings, D. L. Herr, P. W. Hitchon, L. F. Marshall, R. P. Nockels, V. Pascale, P. L. Perot, J. Piepmeier, V. K. Sonntag, F. Wagner, J. E. Wilberger, H. R. Winn, and W. Young. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the third national acute spinal cord injury randomized controlled trial. National acute spinal cord injury study. JAMA 277:1597-604 (1997).
2. J. L. Segal, B. F. Malthy, M. I. Langdorf, R. Jacobson, S. R. Brunnemann, and W. J. Jusko. Methylprednisolone disposition kinetics in patients with acute spinal cord injury. Pharmacotherapy 18:16-22 (1998).
3. J. Vaquero, M. Zurita, S. Oya, C. Aguayo, and C. Bonilla. Early administration of methylprednisolone decreases apoptotic cell death after spinal cord injury. Histol. Histopathol. 21:1091-102 (2006).
4. J. Xu, G. Fan, S. Chen, Y., Wu, X. M. Xu, and C. Y. Hsu. Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res. Mol. Brain Res. 59:135-142 (1998).
5. P. Yan, J. Xu, Q. Li, S., Chen, G. M. Kim, C. Y. Hsu, and X. M. Xu. Glucocorticoid receptor expression in the spinal cord after traumatic injury in adult rats. J. Neurosci. 19:9355-9363 (1999).
6. xL expression after contusion to the rat spinal cord. J. Neurotrauma. 18:1267-1278 (2001).
7. O. Nesic-Taylor, D. Cittelly, Z. Ye, G. Y. Xu, G. Unabia, J. C. Lee, N. M Svrakic, X. H. Liu, R. J. Youle, T. G. Wood, D. McAdoo, K. N. Westlund, C. E. Husebosch, and J. R. Perez-Polo. Exogneous bcl-xL fusion protein spares neurons after spinal cord injury. J. Neursci. Res. 79:628-637 (2005).
8. R. D. Stevens, A. Bhardwaj, J. R. Kirsch, and M. A. Mirski. Critical care and perioperative management in traumatic spinal cord injury. J. Neurosurg. Anesthesiol. 15:215-229 (2003).
9. C. Pozzi, P.G. Bolasco, G. B. Fogazzi, S. Andrulli, P. Altieri, C. Ponticelli, and F. Locatelli. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883-887 (1999).
10. M. S. Nash. Known and plausible modulators of depressed immune functions following spinal cord injuries. J. Spinal. Cord. Med. 23:111-120 (2000).
11. H. Derendorf, H. Mollmann, M. Krieg, S., Tunn, C. Mollmann, J. Barth, and H. J. Rothig. Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Pharm. Res. 8:263-268 (1991).
12. J. C. Drummond, and S. S. Moore. The influence of dextrose administration on neurologic outcome after temporary spinal cord ischemia in the rabbit. Anesthesiology 70:64-70 (1989).
13. L. C. Weaver, D. Gris, L. R. Saville, M. A. Oatway, Y. Chen, D. R. Marsh, E. F. Hamilton, and G. A. Dekaban. Methylprednisolone causes minimal improvement after spinal cord injury in rats, contrasting with benefits of an anti-integrin treatment. J. Neurotrauma. 22:1375-1387 (2005).
14. K. L. Koszdin, D. D. Shen, and C. M. Bernards. Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-Glycoprotein. Anesthesiology 92:156-163 (2002).
15. C. M. Bernards, and T. Akers. Effect of postinjury intravenous or intrathecal methylprednisolone on spinal cord excitatory amino-acid release, nitric oxide generation, PGE(2) synthesis, and myeloperoxidase content in a pig model of acute spinal cord injury. Spinal Cord 44:33-37 (2006).
16. A. Oka, M. Oda, H. Saitoh, A. Nakayama, M., Takada, and B. J. Aungst. Secretory transport of methylprednisolone possibly mediated by P-Glycoprotein in Caco-2 Cells. Biol. Pharm. Bull. 25:393-396 (2002).
17. B. Davidson, and B. Roessler. Adenoviral-mediated gene transfer: Potential therapeutic applications. In M. G. Kaplitt, and A. D. Loewy (eds.), Viral Vectors: Gene Therapy and Neuroscience Applications, Academic, San Diego, 1997, pp. 173-189.
18. N. M. Boulis, N. E. Willmarth, D. K. Song, E. L., Feldman, and M. J. Imperiale. Intraneural colchicines inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery 52:381-387 (2001).
19. G. S. Kwon, and K. Kataoka. Block copolymer micelles as long circulating drug vehicles. Adv. Drug Deliv. Rev. 21:77-80 (1995).
20. A. V. Kabanov, P. Lemieux, S. Vinogradov, and V., Alakhov. Pluronic block copolymers: a novel functional molecules for gene therapy. Adv. Drug Deliv. Rev. 54:223-233 (2002).
21. J. Liaw, T. Aoyagi, K. Kataoka, Y. Sakurai, and T. Okano. Permeation of PEO-PBLA-FITC polymeric micelles in aortic endothelial cell. Pharm. Res. 16:213-220 (1999).
22. H. M. Aliabadi, D. R. Brocks, and A. Lavasanifar. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials 26:7251-7259 (2005).
23. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer. Biodegradable long circulating nanospheres. Science 263:1600-1603 (1994).
24. M. Yokoyama, S. Fukushima, R. Uehara, K. Okamoto, K. Kataoka, Y. Sakurai, and T. Okano. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J. Control. Rel. 50:79-92 (1998).
25. J. Liaw, and T. C. Lin. Evaluation of PEO-PPO-PEO gels as a release vehicle for percutaneous fentanyl. J. Control. Rel. 68:273-282 (2000).
26. E. V. Batrakova, S. Li, V. Alakhov, D. W. Miller, and A. V., Kabanov. Optimal structural requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 304:845-854 (2003).
27. S. M. Moghimi, C. Hunter, and J. C. Murray. Long-circulating and target-specific nanoparticles: theory to practice. Pharmcol. Rev. 53:283-318 (2003).
28. D. C. Litzinger, A. M. Buiting, and N. Van Rooijen. Effect of liposome size on the circulation time and into organ distribution of amphipathic poly(ethylene glycol)-containing liposome. Biochim. Biophys. Acta. 1190:99-107 (1994).
29. C. Allen, A. Eisenberg, J. Mrsic, and D. Maysinger. PCL-PEO micelles as a delivery vehicles for FK506: assessment of a functional recovery of crushed peripheral nerve. Drug Deliv. 7:139-145 (2000).
30. D. M. Faulkner, S. T. Sutton, J. D. Hesford, B. C., Faulkner, D. A. Major, T. B. Hellewell, M. M. Laughon, G. T. Rodeheaver, and R. F. Edlich. A new stable pluronic F68 gel carrier for antibiotics in contaminated wound treatment. J. Emerg. Med. 15:20-24 (1997).
31. Y. C. Chao, S. F. Chang, S. C. Lu, T. C. Hwang, W. H. Hsieh, and J. Liaw. Ethanol enhanced in vivo gene delivery with non-ionic polymeric micelles inhalation. J. Control. Rel. 118:105-117 (2007).
32. Y. C. Tong, S. F. Chang, C. Y. Liu, W. W. Y. Kao, C. H. Huang, and J. Liaw. Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J Gene Med. 9:956-966 (2007).
33. S. Y. Tsai, L. Y. Yang, C. H. Wu, S. F. Chang, C. Y. Hsu, C. P. Wei, S. J. Leu, J. Liaw, Y. H. Lee, and M. D. Tsai. Injury-induced Janus kinase/protein kinase C-dependent phosphorylation of growth-associated protein 43 and signal transducer and activator of transcription 3 for neurite growth in dorsal root ganglion. J. Neurosci. Res. 85(2):321-331 (2007).
34. S. F. Chang, Y. Y. Sun, L. Y. Yang, S. Y. Hu, S. Y. Tsai, W. S. Lee, and Y. H. Lee. Bcl-2 gene family expression in the brain of rat offspring after gestational and lactational dioxin exposure. Ann. N.Y. Acad. Sci. 1042:471-480 (2005).
35. Y. Hanazono, K. E., Brown, A. Handa, M. E. Metzger, D. Heim, G. J. Kurtzman, R. E. Donahue, and C. E. Dunbar. In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. Blood 94:2263-2270 (1999).
36. C. Brand, E. Burkhardt, F. Schaeffel, J. W. Choi, and M. P. Feldkaemper. Regulation of Egr-1, VIP, and Shh mRNA and Egr-1 protein in the mouse retina by light and image quality. Mol. Vis. 28:309-320 (2005).
37. S. F. Chang, H. Y. Chang, Y. C. Tong, S. H. Chen, F. C. Hsaio, S. C. Lu, and J. Liaw. Nonionic polymeric micelles for oral gene delivery in vivo. Human Gene Ther. 15:481-493 (2004).
38. O. Majid, F. Akhlaghi, T. Lee, D. W., Holt, and A. Trull. Simultaneous determination of plasma prednisolone, prednisone, and cortisol levels by high-performance liquid chromatography. Ther. Drug Monitor 23:163-168 (2001).
39. W. F. Ebling, S. J. Szefler, and W. J. Jusko. Methylprednisolone disposition in rabbits. Analysis, prodrug conversion, reversible metabolism, and comparison with man. Drug Metab. Dispos. 13:296-304 (1985).
40. W. Piekosewski, F. S. Chow, and W. J. Jusko. Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in Rabbits. J. Pharmacol. Exp. Ther. 269:103-109 (1994).
41. X. Zhang, and R. Mehvar. Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: dose-dependent pharmacokinetics in rats. Int. J. Pharm. 229:173-182 (2001).
42. J. Schmidt, J. M. Metselaar, M. H. M. Wauben, K. V. Toyka, G. Strom, and R. Gold. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in model of multiple sclerosis. Brain 126:1895-1904 (2003).
43. J. S. Tan, D. E. Butterfield, C. L. Voycheck, K. D. Caldwell, and J. T. Li. Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. Biomaterials 14:823-833 (1993).
44. J. M. Grindel, T. Jaworski, R. M. Emanuele, and P. Culbreth. Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog, and man. Biopharm & Drug Disposit 23:87-103 (2002).
45. E. V. Batrakova, S. Li, Y. Li, V. Y. Alakhov, W. F. Elmquist, and A. V. Kabanov. Distribution kinetics of a micelle-forming block copolymer pluronic 85. J. Control. Rel. 100:389-397 (2004).
46. V. P. Sant, D. Smith, and J. C. Leroux. Enhancement of oral bioavailability of poorly water-soluble drugs by PEO-PAAMA self assemblies. J. Control. Rel. 104:289-300 (2005).
47. A. S. Parsadanian, Y. Cheng, C. R. Keller-Peck, D. M. Holtzman, and W. D. Snider. Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. J. Neurosci. 18:1009-1019 (1998).
48. J. Schmit, R. Gold, L. Schnoroch, U. K. Zettl, H. P. Hartung, and K. V. Toyka. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 123:1431-1441 (2000).
49. T. Y. Yune, S. J. Kim, S. M. Lee, Y. K. Lee, Y. J. Oh, Y. C. Kim, G. J. Markelonis, and T. H. Oh. Systemic administration of 17 beta-estradiol reduces apoptotic cell death and improves functional recovery following traumatic spinal cord injury in rats. J. Neurotrauma. 21:293-306 (2004).
50. G. Cao, W. Pei, H. Ge, Q. Liang, Y. Luo, F. R. Sharp, A. Lu, R. Ran, S. H. Graham, and J. Chen. In vivo delivery of a bcl-xl fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22:5423-5431 (2002).
51. S. Y. Tsai, P. Y. Chiu, C. P. Yang, and Y. H. Lee. Synergistic effects of corticosterone and kainic acid on neurite outgrowth in axotomized doral root ganglion. Neurosci. 114:55-67 (2002).